Barclays Reiterates Overweight Rating on Madrigal Pharmaceuticals, Inc. (MDGL)

Market Context

Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $482.00 with a market capitalization of $12.7B. The stock has gained 54.4% over the past 52 weeks.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Madrigal Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Madrigal Pharmaceuticals, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 03, 2026	Barclays	Overweight	N/A
Jul 29, 2026	Canaccord Genuity	Buy	N/A
Jul 27, 2026	Wells Fargo	Overweight	N/A
Jun 11, 2026	B of A Securities	Neutral	N/A
May 13, 2026	Truist Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View MDGL Stock Page